{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-100902","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.087772+00:00","generated_at":"2026-05-17T22:26:00.536116+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MindMed Q2 2025 net loss widens to $42.7M; cash $237.9M; Phase 3 trials on track","bullets":["Net loss of $42.7M in Q2 2025 vs $5.9M in Q2 2024, driven by higher R&D and warrant fair value changes.","Cash, cash equivalents and investments totaled $237.9M as of June 30, 2025, sufficient into 2027.","R&D expenses rose to $29.8M from $14.6M YoY, primarily due to MM120 ODT program advancement.","Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) and Emerge (MDD) data in 2H 2026.","Appointed Brandi L. Roberts as CFO, bringing over 25 years of life sciences financial leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-100902","json":"https://secwatch.observer/filing/0000950170-25-100902.json","markdown":"https://secwatch.observer/filing/0000950170-25-100902.md","text":"https://secwatch.observer/filing/0000950170-25-100902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/0000950170-25-100902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:26:00.536116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}